{"id":68435,"date":"2025-06-01T12:01:42","date_gmt":"2025-06-01T12:01:42","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/06\/01\/inxmed-announces-promising-phase-ib-ii-clinical-data-for-ifebemtinib-kras-g12c-inhibitor-in-kras-g12c-mutant-solid-tumors-at-asco-2025\/"},"modified":"2025-06-01T12:01:42","modified_gmt":"2025-06-01T12:01:42","slug":"inxmed-announces-promising-phase-ib-ii-clinical-data-for-ifebemtinib-kras-g12c-inhibitor-in-kras-g12c-mutant-solid-tumors-at-asco-2025","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/inxmed-announces-promising-phase-ib-ii-clinical-data-for-ifebemtinib-kras-g12c-inhibitor-in-kras-g12c-mutant-solid-tumors-at-asco-2025\/","title":{"rendered":"InxMed Announces Promising Phase Ib\/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025"},"content":{"rendered":"
\n

NANJING<\/span>, China<\/span><\/span>, June 1, 2025<\/span><\/span> \/PRNewswire\/ — InxMed Co., Ltd, a clinical-stage biotechnological\u00a0company,\u00a0pioneering\u00a0therapies to\u00a0transform cancer treatment, released\u00a0latest clinical data from a Phase Ib\/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of ifebemtinib (IN10018), an oral focal adhesion kinase (FAK) inhibitor in combination with garsorasib (D-1533), an oral KRAS G12C inhibitor, in KRAS G12C mutant solid tumors.<\/p>\n

The clinical data presented at the 2025 ASCO\u00a0Annual\u00a0Meeting\u00a0(Abstract\u00a0#8629 | Poster Board #109)\u00a0included results from two cohorts:<\/p>\n

    \n
  1. Durability follow-up data of the single-arm cohort in first-line\u00a0KRAS G12C-mutant non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 expression, who received ifebemtinib + garsorasib treatment.<\/li>\n
  2. A randomized cohort in previously treated\u00a0KRAS G12C-mutant colorectal cancer (CRC) patients comparing ifebemtinib+ garsorasib versus garsorasib monotherapy.\u00a0<\/li>\n<\/ol>\n

    In NSCLC cohort, the combination of ifebemtinib and garsorasib, as a dual-oral, chemotherapy-free regimen, demonstrated compelling clinical benefit including high response rates and durable efficacy, regardless of PD-L1 expression, and in CRC cohort, the result showed clear add-on efficacy by ifebemtinib compared to KRAS inhibitor monotherapy.<\/p>\n

    Key <\/b>Highlights in First-line <\/b>NSCLC: Dual-Oral Regimen Shows\u00a0Durable\u00a0Efficacy<\/b>\u00a0and Emerging Survival Benefit<\/b>\u00a0<\/p>\n

    As of March 31, 2025<\/span>, 33 first-line\u00a0NSCLC patients, regardless of PD-L1 expression, were enrolled and received the combination of ifebemtinib and garsorasib, with a median follow-up of 16.0 months.\u00a0Previously the company has reported an Objective\u00a0Response rate (ORR) of 90.3% (data presented at ESMO 2024). The follow-up data were now summarized as follows: \u00a0<\/p>\n